Hepatitis B Virus Reactivation in Patients With Marginal Zone B-cell Lymphoma After Rituximab Containing Treatment: Consortium for Improving Survival of Lymphoma (CISL) Marginal Zone Lymphoma Cohort Study (MARCO)
Sponsor study identifier
observational
500
1 country
1
Study Start
March 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Marginal zone lymphoma is a rare of subtype of Non-Hodgkin Lymphoma. Because of its rarity, prospective clinical trial is difficult to conduct. Therefore we want to make prospective MZL patients' cohort for several observation study
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2013
Date type not reportedThis date has not been verified as actual or estimated.
April 4, 2016
Actual (reported)April 8, 2016
Actual (reported)February 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
February 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Hepatitis B virus reactivation in patients with marginal zone B-cell lymphoma after rituximab containing treatment
Rate of HBV reactivation
up to 12 months
Cohort observation study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The patients who is diagnosed as a marginal zone lymphoma- nodal MZL, marginal zone lymphoma of MALT type, splenic MZL
Sung Yong Oh
Busan, 602-715, South Korea
Sung Yong Oh
Consortium for improving survival of lymphoma office
First Submitted
April 4, 2016
First Posted
April 8, 2016
Study Start
March 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2020
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 18, 2018
Record last verified: 2018-04
We will share collected data with participated investigators in Korea
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: